Captopril

Angiotensin Converting Enzyme Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Captopril is an ofp drug in the Angiotensin Converting Enzyme Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1981. Its mechanism of action is classified as Angiotensin-converting Enzyme Inhibitors. DrugCentral lists 13 molecular targets, including ACE, REN and ACE. Recorded indications include Chronic heart failure, Diabetic renal disease, Hypertensive disorder and Left ventricular cardiac dysfunction.

• Approval status: ofp (first approved 1981 by the FDA).
• Drug class: Angiotensin Converting Enzyme Inhibitor.
• Mechanism of action: Angiotensin-converting Enzyme Inhibitors.
• Molecular targets: ACE, REN, ACE and Ace (13 listed in DrugCentral).
• Indications: Chronic heart failure, Diabetic renal disease, Hypertensive disorder and Left ventricular cardiac dysfunction.
• ATC code: C09AA01 (ACE inhibitors, plain).
• Molecular formula: C9H15NO3S; molecular weight 217.29 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (4)

• Chronic heart failure
• Diabetic renal disease
• Hypertensive disorder
• Left ventricular cardiac dysfunction

Off-label uses (5)

• Atrial fibrillation
• Cystine Renal Calculi
• Cystinuria
• Diastolic heart failure
• Nondiabetic Proteinuric Nephropathy

Contraindications (38)

• Acute cerebrovascular insufficiency
• Acute pancreatitis
• Angioedema
• Anuria
• Aortic valve stenosis
• Azotemia
• Bone marrow depression
• Cough
• Dehydration
• Diabetes mellitus
• Disease of liver
• Disorder of connective tissue
• Gout
• Hemodialysis with High-Flux Membrane
• Hepatic coma
• Hereditary angioneurotic edema
• Hypercalcemia
• Hypercholesterolemia
• Hyperkalemia
• Hyperparathyroidism
• Hypertrophic cardiomyopathy
• Hyperuricemia
• Hypochloremic alkalosis
• Hypokalemia
• Hypomagnesemia
• Hyponatremia
• Hypovolemia
• Immunosuppression
• Kidney disease
• Low blood pressure
• + 8 more

Mechanism & targets

• Mechanism of action (MoA): Angiotensin-converting Enzyme Inhibitors
• Established pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Molecular targets (13)

Target	Gene	Action	Activity
Angiotensin-converting enzyme	ACE	unknown	Ki 8.77
Renin	REN	unknown	Ki 8.77
Angiotensin-converting enzyme	ACE	inhibitor	Ki 8.70
Angiotensin-converting enzyme	Ace	unknown	Ki 8.70
Prothrombin	F2	unknown	Ki 7.32
Leukotriene A-4 hydrolase	LTA4H	unknown	IC50 7.15
Beta-lactamase class B VIM-2	blaVIM-2	unknown	Kd 6.22
Succinyl-diaminopimelate desuccinylase	dapE	unknown	Ki 5.74
Beta-lactamase	blaIMP-1	unknown	Ki 5.62
Prostaglandin G/H synthase 2	PTGS2	unknown	Ki 4.92
Beta-lactamase NDM-1	blaNDM-1	unknown	Kd 4.85
Prostaglandin G/H synthase 1	PTGS1	unknown	Ki 4.77
Beta-lactamase II	bla2	unknown	Ki 4.75

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1981-04-06	FDA	—	PAR PHARM

ATC classification

ATC code	Therapeutic hierarchy
C09AA01	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
C09BA01	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cardiac failure congestive	132.9
Segmental diverticular colitis	98.1
Pedal pulse abnormal	90.8
Myocardial infarction	85.1
Hypokalaemia	77.7
Cyanosis	77.6
Hyponatraemia	75.0
Renal failure	74.8
Calcium ionised decreased	73.3
Reduced facial expression	72.2
Toxic epidermal necrolysis	71.6
Scleroderma renal crisis	66.3

Chemical structure

• Molecular formula: C₉H₁₅NO₃S
• Molecular weight: 217.29 g/mol
• CAS number: —
• InChIKey: FAKRSMQSSFJEIM-RQJHMYQMSA-N
• PubChem CID: 44093

C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Captopril used for?

DrugCentral lists the following indications for Captopril: Chronic heart failure, Diabetic renal disease, Hypertensive disorder and Left ventricular cardiac dysfunction.

How does Captopril work?

Captopril is classified as Angiotensin-converting Enzyme Inhibitors; its molecular targets in DrugCentral include ACE, REN, ACE (inhibitor) and Ace.

When was Captopril first approved?

Captopril was first approved by the FDA in 1981.

What drug class does Captopril belong to?

Captopril is in the Angiotensin Converting Enzyme Inhibitor class.

What is the chemical formula of Captopril?

Captopril has the molecular formula C9H15NO3S and a molecular weight of 217.29 g/mol.

Sources

• DrugCentral drug card 484 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1560 — compound record and bioactivity
• PubChem CID 44093 — chemical identifiers
• DrugBank DB01197 — drug record
• FDA UNII 9G64RSX1XD — substance identity
• DailyMed: FDA labels for Captopril — current prescribing information (label search)
• UniProt P00797 (REN) — target protein
• UniProt P12821 (ACE) — target protein
• UniProt P00734 (F2) — target protein
• UniProt P09960 (LTA4H) — target protein
• UniProt P35354 (PTGS2) — target protein
• UniProt P23219 (PTGS1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.